You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

NSCLC-squamous

Showing 1 - 25 of 5,920
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Non-squamous NSCLC Trial (biological, drug, dietary supplement)

Not yet recruiting
  • Non-squamous NSCLC
  • Pembrolizumab
  • +7 more
  • (no location specified)
Feb 20, 2023

Non Squamous Non Small Cell Lung Cancer, EGFR Positive NSCLC Trial (Toripalimab plus Chemotherapy)

Not yet recruiting
  • Non Squamous Non Small Cell Lung Cancer
  • EGFR Positive Non-small Cell Lung Cancer
  • Toripalimab plus Chemotherapy
  • (no location specified)
Jul 28, 2023

Non-squamous NSCLC Trial in Nanjing (paclitaxel polymeric micelles for injection)

Not yet recruiting
  • Non-squamous NSCLC
  • paclitaxel polymeric micelles for injection
  • Nanjing, Jiangsu, China
  • +1 more
Mar 13, 2023

NSCLC Trial in Pittsburgh (M1774, Cemiplimab)

Not yet recruiting
  • Non-Small Cell Lung Cancer
  • Pittsburgh, Pennsylvania
    UPMC Cancer Center
May 22, 2023

NSCLC Trial in Wuhan (Cadonilimab, Pemetrexed, Carboplatin)

Recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Wuhan, Hubei, China
    Qian Chu
Aug 18, 2023

NSCLC Trial in Pittsburgh (Tiragolumab, Atezolizumab, Pemetrexed)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • Pittsburgh, Pennsylvania
    UPMC Hillman Cancer Center
Feb 16, 2023

NSCLC Trial (PM8002, Placebo, Carboplatin)

Not yet recruiting
  • NSCLC
  • (no location specified)
Feb 23, 2023

Advanced Non-squamous Non-small-cell Lung Cancer, Recurrent Non-Squamous NSCLC, Metastatic Non-squamous Non Small Cell Lung

Not yet recruiting
  • Advanced Non-squamous Non-small-cell Lung Cancer
  • +2 more
  • Beijing, Beijing, China
    Peking University First Hospital Ethics Committee
Sep 10, 2023

Non-squamous Non-small-cell Lung Cancer Trial in Hangzhou (Tusamitamab ravtansine+Sintilimab+Carboplatin or

Not yet recruiting
  • Non-squamous Non-small-cell Lung Cancer
  • Tusamitamab ravtansine+Sintilimab+Carboplatin or Cisplatin+Pemetrexed
  • +2 more
  • Hangzhou, Zhejiang, China
    Zhejiang Cancer Hospital
May 5, 2023

NSCLC Trial (Ivonescimab Injection, Pembrolizumab Injection)

Not yet recruiting
  • Non-Small Cell Lung Cancer
  • Ivonescimab Injection
  • Pembrolizumab Injection
  • (no location specified)
Jun 9, 2023

Squamous Cell NSCLC Trial in Hangzhou (Sintilimab, Carboplatin, Albumin-Bound Paclitaxel)

Not yet recruiting
  • Squamous Cell Non-small Cell Lung Cancer
  • Sintilimab
  • +2 more
  • Hangzhou, Zhejiang, China
    Second Affiliated Hospital, School of Medicine, Zhejiang Univers
Jun 19, 2022

NSCLC Stage II, Bevacizumab, Immunotherapy Trial in Guangzhou (Serplulimab combined with bevacizumab and first-line chemo)

Not yet recruiting
  • Non-small Cell Lung Cancer Stage II
  • +3 more
  • Serplulimab combined with bevacizumab and first-line chemotherapy
  • Guangzhou, Guangdong, China
    Likun Chen
Apr 10, 2023

NSCLC Trial in Wuhan (Adebrelimab Combined With Bevacizumab and Albumin Paclitaxel)

Recruiting
  • Non-small Cell Lung Cancer
  • Adebrelimab Combined With Bevacizumab and Albumin Paclitaxel
  • Wuhan, Hubei, China
    Union hospital
Feb 20, 2023

Advanced Squamous Non Small Cell Lung Cancer Trial in Dallas (Afatinib + Prednisone)

Recruiting
  • Advanced Squamous Non Small Cell Lung Cancer
  • Afatinib + Prednisone
  • Dallas, Texas
    UT Southwestern Medical Center
Jun 28, 2022

NSCLC, Stage III Trial in Beijing (Tislelizumab, Pemetrexed (Nonsquamous NSCLC) or Paclitaxel/Nab-paclitaxel(Squamous NSCLC),

Recruiting
  • NSCLC, Stage III
  • Beijing, Beijing, China
    Beijing Tsinghua Chang Gung Hospital
Nov 4, 2022

Squamous NSCLC, Non-Squamous NSCLC Trial (Durvalumab, Tremelimumab)

Withdrawn
  • Squamous Non-small Cell Lung Cancer
  • Non-Squamous Non-small Cell Lung Cancer
  • (no location specified)
Dec 17, 2021

Lung Cancer, Non Small Cell Lung Cancer, Adenocarcinoma of Lung Trial run by the National Cancer Institute (NCI) (LMB-100,

Active, not recruiting
  • Lung Cancer
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Oct 4, 2022

NSCLC, Brain Tumors Trial (bevacizumab, First-Line Chemotherapy Agents, Second-Line Chemotherapy Agents)

Completed
Has Results
  • Non-Small Cell Lung Cancer
  • Brain Neoplasms
  • (no location specified)
Dec 9, 2022

Non-Squamous NSCLC (NSCLC), Adenocarcinoma of the Lung, Lung Cancer Trial in United States (Docetaxel, Nivolumab, Gemcitabine)

Terminated
Has Results
  • Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
  • +3 more
  • Anderson, Indiana
  • +8 more
Jul 7, 2022

Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line

Completed
  • Non-squamous NSCLC
    • Changsha, Hunan, China
      Hunan Cancer Hospital
    Mar 1, 2022

    Non-squamous NSCLC, EGFR Gene Mutation Trial in Chengdu (Tislelizumab Combined With Bevacizumab and Platinum Plus Pemetrexed)

    Not yet recruiting
    • Non-squamous Non-small Cell Lung Cancer
    • EGFR Gene Mutation
    • Tislelizumab Combined With Bevacizumab and Platinum Plus Pemetrexed
    • Chengdu, Sichuan, China
    • +2 more
    May 24, 2022

    Non-squamous Non-small-cell Lung Cancer, Brain Metastases Trial in Guangzhou (Camrelizumab, Pemetrexed, Carboplatin)

    Active, not recruiting
    • Non-squamous Non-small-cell Lung Cancer
    • Brain Metastases
    • Guangzhou, Guangzhou, China
      Li-Kun Chen
    Nov 13, 2022

    NSCLC, NSCLC Stage IV, NSCLC Stage IIIB Trial (MYTX-011)

    Not yet recruiting
    • NSCLC
    • +5 more
    • (no location specified)
    Dec 7, 2022

    Under Immunotherapy in Metastatic NSCLC: Sputum, Blood Samples

    Recruiting
    • Non-squamous Lung Cancer
    • Metastatic Lung Cancer
    • Blood
    • +3 more
    • Tours, France
      University hospital
    Nov 7, 2022

    Non-squamous NSCLC Trial in Guangzhou (FSRT combined with Bevacizumab)

    Active, not recruiting
    • Non-squamous Non-small Cell Lung Cancer
    • FSRT combined with Bevacizumab
    • Guangzhou, China
      Sun Yat-sen University
    Nov 25, 2022